AIM NYSE Biological Products, (No Diagnostic Substances) Financials FY2016βFY2025
AIM ImmunoTech Inc. had $0.1M of revenue in fiscal 2025, down 48.2% on the year before. Over five years, revenue changed β11.6% a year on average.
Last close Β· Oct 23, 2026
$0.16
2.9%Hi! I read AIM ImmunoTech Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β48.2%
No. Sales fell 48.2% last year.
Does it make a profit?
β15,861.4%
No. It lost money last year.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days AIM ImmunoTech Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 16, 2026
Monday Β· in 22 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 7, 2026 | Q2 '26 | Time not announced | 8-K β |
| May 15, 2026 | Q1 '26 | After the market closes | 10-Q β |
| Mar 27, 2026 | Q4 '25 | After the market closes | 10-K β |
| Nov 17, 2025 | Q3 '25 | After the market closes | 10-Q β |
| Aug 14, 2025 | Q2 '25 | After the market closes | 10-Q β |
| May 15, 2025 | Q1 '25 | After the market closes | 10-Q β |
| Mar 27, 2025 | Q4 '24 | Before the market opens | 10-K β |
| Nov 14, 2024 | Q3 '24 | After the market closes | 10-Q β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· AIM ImmunoTech Inc. had $0.1M of revenue in fiscal 2025, down 48.2% on the year before. Over five years, revenue changed β11.6% a year on average. Its operating margin was β13,254.5%, down 1,624.0Β pts: of every 100 in sales, about β13,255 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· AIM ImmunoTech Inc. lost $14.0M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· AIM ImmunoTech Inc. owes $1.4M more than it holds in cash.
Cash, debt and the ratios that show how comfortably AIM ImmunoTech Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $48.3M | $34.2M | $13.1M | $4.0M | $3.0M |
| Debt incl. finance leases | β | β | β | $2.8M | $4.5M |
| Interest coverage | β281.2x | β | β | β33.8x | β14.4x |
| Current ratio | 74.6x | 26.7x | 1.7x | 0.4x | 0.5x |
| Quick ratio | 74.6x | 26.7x | 1.7x | 0.4x | 0.5x |
| Total assets | $57.7M | $40.5M | $19.4M | $8.6M | $5.8M |
| Total liabilities | $0.8M | $2.0M | $9.1M | $9.9M | $15.6M |
| Shareholders' equity | $56.9M | $38.5M | $10.2M | β$1.3M | β$9.8M |
| Net debt (β = net cash) | β | β | β | β$1.2M | $1.4M |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· AIM ImmunoTech Inc. passes 2 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 2 / 7 | 1 / 7 | 4 / 8 | 4 / 8 | 2 / 7 | 2 / 7 | 2 / 7 | 3 / 7 | 2 / 8 |
| Accruals ratio | β0.6% | β1.9% | 5.8% | β1.9% | β9.4% | β8.4% | β6.8% | β25.7% | β17.4% | β41.7% |
| Altman Z'' | β50.43 | β74.22 | β80.59 | β50.61 | 4.71 | 55.87 | β8.29 | β76.77 | β181.31 | β266.06 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $0.1M | $0.4M | $0.4M | $0.1M | $0.2M | $0.1M | $0.1M | $0.2M | $0.2M | $0.1M |
| Research and development | $5.1M | $4.1M | $4.8M | $4.7M | $5.7M | $7.7M | $7.0M | $10.9M | $6.2M | $3.9M |
| Operating income | β$13.8M | β$11.4M | β$11.5M | β$12.4M | β$15.2M | β$18.8M | β$19.9M | β$31.9M | β$19.8M | β$11.7M |
| Interest expense | β | β | $0.2M | $0.4M | $0.7M | $0.1M | β | β | $0.6M | $0.8M |
| Pretax income | β | β | β | β | β | β | β | β | β | β$14.0M |
| Net income | β$7.5M | β$8.3M | β$9.8M | β$9.4M | β$14.4M | β$19.1M | β$19.4M | β$29.0M | β$17.3M | β$14.0M |
| Diluted EPS | β$0.34 | β$0.29 | β$9.77 | β$2.58 | β$0.45 | β$0.40 | β$0.40 | β$0.60 | β$30.92 | β$8.62 |
| Diluted shares | 0.02B | 0.03B | 0.00B | 0.00B | 0.03B | 0.05B | 0.05B | 0.05B | 0.00B | 0.00B |
| Cash flow | ||||||||||
| Cash from operations | β$7.4M | β$7.9M | β$10.6M | β$9.1M | β$10.4M | β$14.0M | β$16.1M | β$21.3M | β$14.9M | β$11.0M |
| Capital expenditure | $0.2M | $0.0M | $0.1M | $0.1M | $0.0M | $0.0M | $0.1M | β | $0.0M | β |
| Free cash flow | β$7.5M | β$8.0M | β$10.7M | β$9.1M | β$10.4M | β$14.0M | β$16.2M | β | β$14.9M | β |
| Depreciation and amortization | $1.1M | $0.9M | $0.9M | $0.7M | $0.7M | $0.7M | $0.0M | $0.0M | $0.0M | $0.0M |
| Stock-based compensation | $0.1M | $0.6M | $0.9M | $0.9M | $1.0M | $1.6M | $1.0M | $0.2M | $0.7M | $0.1M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $2.4M | $1.4M | $0.3M | $8.8M | $54.4M | $48.3M | $34.2M | $13.1M | $4.0M | $3.0M |
| Total debt | β | β | $2.5M | $2.3M | $2.1M | β | β | β | $2.8M | $4.5M |
| Current assets | $6.9M | $3.5M | $3.8M | $10.4M | $40.3M | $50.2M | $36.3M | $14.6M | $4.2M | $3.3M |
| Current liabilities | $2.4M | $2.7M | $5.3M | $1.1M | $1.1M | $0.7M | $1.4M | $8.7M | $9.5M | $6.2M |
| Property and equipment, net | $9.5M | $8.6M | $7.8M | $7.1M | $6.5M | $4.0M | $0.2M | $0.1M | $0.1M | $0.1M |
| Intangible assets | $0.9M | $0.9M | $0.9M | $1.2M | $1.5M | $2.0M | $1.9M | $2.3M | $2.6M | $1.7M |
| Total assets | $18.9M | $14.2M | $13.8M | $20.8M | $64.6M | $57.7M | $40.5M | $19.4M | $8.6M | $5.8M |
| Total liabilities | $3.4M | $5.5M | $8.3M | $7.3M | $3.3M | $0.8M | $2.0M | $9.1M | $9.9M | $15.6M |
| Preferred stock | β | β | β | $0.8M | $0.7M | $0.7M | $0.7M | β | β | β |
| Shareholders' equity | $15.5M | $8.7M | $5.6M | $13.4M | $61.3M | $56.9M | $38.5M | $10.2M | β$1.3M | β$9.8M |
| Margins | ||||||||||
| Operating margin | β15,004.3% | β2,612.4% | β3,132.4% | β8,887.9% | β9,295.7% | β13,954.1% | β14,129.8% | β15,800.0% | β11,630.6% | β13,254.5% |
| EBITDA margin | β13,788.0% | β2,395.4% | β2,899.2% | β8,362.9% | β8,887.7% | β13,465.9% | β14,102.8% | β15,780.7% | β11,608.8% | β13,212.5% |
| Net margin | β8,154.3% | β1,889.9% | β2,677.7% | β6,717.1% | β8,834.4% | β14,168.1% | β13,790.8% | β14,337.6% | β10,188.2% | β15,861.4% |
| FCF margin | β8,195.7% | β1,821.7% | β2,913.1% | β6,525.0% | β6,374.2% | β10,374.8% | β11,485.1% | β | β8,768.2% | β |
| Returns | ||||||||||
| Return on capital | β | β | β116.5% | β140.8% | β132.7% | β | β | β | β | β |
| Return on capital employed | β84.0% | β99.3% | β134.4% | β63.4% | β23.9% | β33.0% | β50.9% | β297.5% | 2,132.9% | 2,638.9% |
| Return on equity | β48.4% | β68.3% | β137.6% | β98.9% | β38.5% | β32.4% | β40.8% | β118.9% | β388.7% | β |
| Return on assets | β39.7% | β49.9% | β70.1% | β54.4% | β33.7% | β31.3% | β39.6% | β96.8% | β123.8% | β194.0% |
| Return on tangible equity | β51.3% | β105.3% | β210.5% | β76.5% | β24.1% | β34.8% | β53.2% | β365.6% | β | β |
| Growth | ||||||||||
| Revenue growth | β | 375.0% | β16.0% | β61.9% | 16.4% | β17.2% | 4.4% | 43.3% | β15.8% | β48.2% |
| Share count change | β | 31.4% | β96.5% | 262.7% | 774.2% | 48.7% | 1.5% | 1.1% | β98.8% | 188.9% |
| Financial health | ||||||||||
| Debt / equity | β | β | 0.5x | 0.2x | 0.0x | β | β | β | β | β |
| Interest coverage | β | β | β57.2x | β29.1x | β22.5x | β281.2x | β | β | β33.8x | β14.4x |
| Current ratio | 2.9x | 1.3x | 0.7x | 9.3x | 36.6x | 74.6x | 26.7x | 1.7x | 0.4x | 0.5x |
| Quick ratio | 2.9x | 1.3x | 0.7x | 9.3x | 36.6x | 74.6x | 26.7x | 1.7x | 0.4x | 0.5x |
| Capital allocation | ||||||||||
| Capex / revenue | 173.9% | 4.6% | 13.9% | 48.6% | 13.5% | 30.4% | 61.0% | β | 10.6% | β |
| Stock comp / revenue | 56.5% | 130.7% | 253.1% | 609.3% | 635.6% | 1,161.5% | 676.6% | 120.3% | 403.5% | 68.2% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 2.0 | 1.0 | 4.0 | 4.0 | 2.0 | 2.0 | 2.0 | 3.0 | 2.0 |
| Altman Z'' | β50.4 | β74.2 | β80.6 | β50.6 | 4.7 | 55.9 | β8.3 | β76.8 | β181.3 | β266.1 |
| Accruals ratio | β0.6% | β1.9% | 5.8% | β1.9% | β9.4% | β8.4% | β6.8% | β25.7% | β17.4% | β41.7% |
Source: SEC EDGAR XBRL filings (CIK 0000946644). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
